Antigen-to-Surface Enhancement Technology (ASET); an antigen presentation boosting platform for mRNA vaccines

The success of mRNA vaccines against SARS-CoV-2 highlights the revolutionary capabilities of this technology. Its efficacy in combatting other diseases like malaria and respiratory syncytial virus is also ground-breaking, and these advancements are now helping to fuel the development of mRNA-based vaccines targeting cancer. However, despite their promise, current mRNA vaccines also face limitations that hinder their efficacy and increase their manufacturing costs.

We have developed a breakthrough approach for enhancing vaccine efficiency, which we have termed Antigen-to-Surface Enhancement Technology (ASET). Inclusion of ASET in an mRNA vaccine dramatically increases its effectives. ASET is a highly versatile technology that can be used to improve the efficacy of mRNA vaccines against a wide range of diseases, including infectious diseases and cancer, and can also be applied to DNA-based vaccines.

It is also a cost-effective technology, as it can reduce the amount of mRNA required in each vaccine formulation. Benefits of ASET include: * Enhanced effectiveness of mRNA and DNA vaccines. * Reduced potential for reactogenic side-effects. * Broad adaptability to existing and novel vaccines across a range of infectious diseases and cancer.

* Reduced production costs (lower cost-of-goods).

ASET is currently in the preclinical stage of development. In this project, we aim to optimise the ASET prototype and assess its effectiveness against cancer and viral pathogens. The results obtained in this Biomedical Catalyst project will establish ASET as a break-through technology that will be incorporated into the development of the next generation of mRNA and DNA vaccines.